Danish researchers from Statens Serum Institut have developed a vaccine against the sexually transmitted disease, chlamydia. The vaccine is the first of its kind in the world as the disease, which is caused by a bacterial infection, has developed a series of strategies to budge to human immune system and has therefore previously been impossible to develop a vaccine against. Following promising results in initial trails, however, the Danish vaccine is now ready for testing on humans. The first human trial is a so-called phase 1 trial to determine possible side effects and the vaccine’s effect on humans.
The vaccine works by stimulating a genital mucous membrane response to direct the immune system to the mucous membrane where chlamydia infections attack.
Chlamydia is one of the most widespread infections in the world and can cause involuntary childlessness. An estimated 100 million people are infected with chlamydia worldwide. Approx. 30.000 Danes are infected with chlamydia each year.
Statens Serum Institut will collaborate with colleagues at Imperial College London on the clinical trial, and the first results are expected within a year.